Oleg Gladkov

ENTRÉE Lung Platform Trial Sub-study 1: Phase II Randomized Efficacy and Safety Analysis of Feladilimab Plus Docetaxel Versus Docetaxel Monotherapy in Advanced/Recurrent NSCLC

Marina Chiara Garassino, Sophie Cousin, Benjamin Besse, Adrian Sacher et autres

us, fr, ca, ru, ro, es, de (code pays fourni par la source)

Опухоли невыявленной первичной локализации

А. В. Новик, Oleg Gladkov, Е. Н. Имянитов, С. Н. Новиков et autres

kr (code pays fourni par la source)

Corrigendum to “Improved clinical outcomes with low-dose anti-CTLA-4 (Nurulimab) plus anti-PD-1 (Prolgolimab) vs. anti-PD-1 monotherapy in advanced cutaneous melanoma: Results from the phase III OCTAVA trial” [Eur J Cancer. 227 (2025) 115674]

Lev Demidov, Igor Samoylenko, Galina Kharkevich, Kristina V. Orlova et autres

ru, il, us, by, cz, in (code pays fourni par la source)

Improved clinical outcomes with low-dose anti-CTLA-4 (Nurulimab) plus anti-PD-1 (Prolgolimab) vs. anti-PD-1 monotherapy in advanced cutaneous melanoma: Results from the phase III OCTAVA trial

Lev Demidov, Igor Samoylenko, Galina Kharkevich, Kristina V. Orlova et autres

ru, il, us, by, cz, in (code pays fourni par la source)

Results of an international, double-blind, randomized, phase III clinical trial to compare the efficacy and safety of a biosimilar pertuzumab (BCD-178) with reference pertuzumab in patients with HER2-positive breast cancer

Lyudmila Zhukova, E. V. Artamonova, Svetlana Demidova, Konstantin Penkov et autres

ru, by, pl, us, pk, nl, bg, cz, gr (code pays fourni par la source)

Cemiplimab monotherapy as first‐line treatment of patients with brain metastases from advanced non–small cell lung cancer with programmed cell death‐ligand 1 ≥50%

Saadettin Kılıçkap, Mustafa Özgüroğlu, Ahmet Sezer, Mahmut Gümüş et autres

tr, ua, ru, th, us (code pays fourni par la source)

Abstract 653: Proved clinical benefit of low-dose anti-CTLA4 + anti-PD-1 immunotherapy versus mono anti-PD-1 therapy in patients unresectable or metastatic melanoma: Phase III OCTAVA trial

Lev Demidov, Igor Samoylenko, Galina Kharkevich, Kristina V. Orlova et autres

ru, us, by, in (code pays fourni par la source)

Prolgolimab with chemotherapy as first-line treatment for advanced non-squamous non-small-cell lung cancer

K. Laktionov, A. Yu. Smolin, Daniil Stroyakovskiy, В. Моисеенко et autres

es, ru, cn, cz, us, gt, sk, hu (code pays fourni par la source)

Опухоли невыявленной первичной локализации

A.V. Novik Novik, Oleg Gladkov, Е. Н. Имянитов, В. М. Копп et autres

OA11.05 Results of a Phase III Trial of Prolgolimab with Chemotherapy as First-Line Therapy for Patients with Advanced Non-Squamous NSCLC: DOMAJOR

K. Laktionov, A. Yu. Smolin, Daniil Stroyakovsky, В. Моисеенко et autres

es, ru, cn, cz, us, gt, cu, hu, sk, se, iq (code pays fourni par la source)

Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial

Fred Saad, Egils Vjaters, Neal D. Shore, David Olmos et autres

ca, lv, us, es, cn, lt, ru, fi, it, fr, de, in (code pays fourni par la source)

Bempegaldesleukin Plus Nivolumab Versus Sunitinib or Cabozantinib in Previously Untreated Advanced Clear Cell Renal Cell Carcinoma: A Phase III Randomized Study (PIVOT-09)

Nizar M. Tannir, Maria Nirvana Formiga, Konstantin Penkov, Nikolay Kislov et autres

us, br, ru (code pays fourni par la source)